Advances in Preventive and Therapeutic Strategies for Oral Cancer: A Short Review DOI Open Access
Lei Ma, Myoung-Ok Kim

Journal of Cancer Prevention, Journal Year: 2024, Volume and Issue: 29(4), P. 113 - 119

Published: Dec. 30, 2024

Oral cancer is a major global health concern, with high incidence and mortality rates, especially in high-risk populations.Early diagnosis remains challenge, current treatments, such as surgery, radiation, chemotherapy, have limited effectiveness, particularly advanced stages.Recent advances targeted therapies immunotherapy offer promising alternatives, providing more precise personalized treatment options.Targeted therapies, epidermal growth factor receptor inhibitors, aim to disrupt specific molecular pathways tumor growth, while immunotherapies, including immune checkpoint inhibitors chimeric antigen receptor-T cell therapy, enhance the body's response fight cancer.Combination integrating both strategies, are being explored overcome limitations of single-agent treatments.This review highlights strategies prevention oral cancer, discusses emerging explores future research directions, focusing on optimizing existing identifying new biomarkers, developing innovative therapeutic approaches.The potential medicine combination offers hope for improving survival rates quality life patients.

Language: Английский

Nano-Oncologic Vaccine for Boosting Cancer Immunotherapy: The Horizons in Cancer Treatment DOI Creative Commons
Chao Chen, Yue‐Ping Xu, Hui Meng

et al.

Nanomaterials, Journal Year: 2025, Volume and Issue: 15(2), P. 122 - 122

Published: Jan. 16, 2025

Nano-oncologic vaccines represent a groundbreaking approach in the field of cancer immunotherapy, leveraging unique advantages nanotechnology to enhance effectiveness and specificity treatments. These utilize nanoscale carriers deliver tumor-associated antigens immunostimulatory adjuvants, facilitating targeted immune activation promoting robust antitumor responses. By improving antigen presentation localizing within tumor microenvironment, nano-oncologic can significantly increase efficacy particularly when combined with other treatment modalities. This review highlights mechanisms through which operate, their potential overcome existing limitations treatment, ongoing advancements design. Additionally, it discusses delivery approach, such as EPR effects, pH response, ultrasonic magnetic response. The combination therapy effects photothermal therapy, radiotherapy, or checkpoint inhibitors are also discussed. Overall, hold great promise for changing landscape advancing personalized medicine, paving way more effective therapeutic strategies tailored individual patient needs.

Language: Английский

Citations

0
Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols DOI Creative Commons

Michelle A. Camerino,

Davide Giacobino, Lidia Tarone

et al.

Veterinary Quarterly, Journal Year: 2025, Volume and Issue: 45(1), P. 1 - 16

Published: March 10, 2025

Canine oral malignant melanoma (OMM) is an aggressive, spontaneously occurring tumor carrying a poor to guarded prognosis and relatively limited therapeutic strategies. In this landscape, chondroitin sulfate proteoglycan (CSPG)4 represents promising immunotherapeutic target. The objective of bi-center prospective study was examine the clinical outcome OMM-bearing dogs treated with surgery adjuvant electroporation using DNA vaccine (HuDo-CSPG4) encoding both human (Hu) canine (Do) portions CSPG4 through two different vaccination protocols. Dogs stage I-III surgically resected CSPG4-positive OMM underwent HuDo-CSPG4 plasmid starting at 3rd-4th post-operative week; electrovaccination repeated after 2 weeks. protocol 1, then delivered monthly while in 2, performed four additional times followed by semestral boosters. survival rates HuDo-CSPG4-vaccinated were estimated compared control group alone. Significantly longer overall observed vaccinated as non-vaccinated controls. receiving showed similar outcomes those undergoing despite fewer vaccinations. comparable humoral response against resulting from administration 1 appears have relevance, highlighting optimal schedule.

Language: Английский

Citations

0
Clinical Trials of Cancer Immunogene Therapies in Companion Animals: An Update (2017–2024) DOI Creative Commons
Gerardo C. Glikin,

Liliana M.E. Finocchiaro

Veterinary Sciences, Journal Year: 2025, Volume and Issue: 12(4), P. 329 - 329

Published: April 3, 2025

This review summarizes the findings of veterinary clinical trials on immunogene therapy published between 2017 and 2024. Various tumor types, including melanoma (canine feline), mastocytoma (canine), mammary adenocarcinoma osteosarcoma sarcoid (equine), were treated using diverse strategies. Non-viral vectors predominantly used to deliver genes encoding tumor-associated antigens, cytokines, or suicide enzymes. Among these non-viral methods, electrotransfer was most commonly employed technique for introducing therapeutic into cells. Generally, procedures resulted in minimal no adverse side effects, animals often showed significant improvements, such as enhanced quality life, delayed suppressed recurrence metastasis, increased survival times. Some innovative approaches hold great potential adjunct therapies standard treatments. The promising outcomes from studies companion strongly support their application oncology provide valuable preclinical data (including safety assessments proof-of-concept studies) analogous human trials.

Language: Английский

Citations

0
Novel Strategies in Breast Cancer Management: from Treatment to Long-term Remission DOI

S Habibi,

Shabbou Bahramian,

Saeedeh Zare Jalise

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104715 - 104715

Published: April 1, 2025

Language: Английский

Citations

0
State-of-the-Art Review on Liposomes as Versatile Cancer Vaccine Delivery Systems DOI

Abulfazl Vatankhah,

Fatemeh Oroojalian,

Sepehr Hoseinzadeh Moghaddam

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106975 - 106975

Published: April 1, 2025

Language: Английский

Citations

0
Vaccines for cancer prevention and treatment DOI
Federica Cavallo, Pier‐Luigi Lollini

Molecular Aspects of Medicine, Journal Year: 2024, Volume and Issue: unknown, P. 101334 - 101334

Published: Dec. 1, 2024

Language: Английский

Citations

0
Advances in Preventive and Therapeutic Strategies for Oral Cancer: A Short Review DOI Open Access
Lei Ma, Myoung-Ok Kim

Journal of Cancer Prevention, Journal Year: 2024, Volume and Issue: 29(4), P. 113 - 119

Published: Dec. 30, 2024

Oral cancer is a major global health concern, with high incidence and mortality rates, especially in high-risk populations.Early diagnosis remains challenge, current treatments, such as surgery, radiation, chemotherapy, have limited effectiveness, particularly advanced stages.Recent advances targeted therapies immunotherapy offer promising alternatives, providing more precise personalized treatment options.Targeted therapies, epidermal growth factor receptor inhibitors, aim to disrupt specific molecular pathways tumor growth, while immunotherapies, including immune checkpoint inhibitors chimeric antigen receptor-T cell therapy, enhance the body's response fight cancer.Combination integrating both strategies, are being explored overcome limitations of single-agent treatments.This review highlights strategies prevention oral cancer, discusses emerging explores future research directions, focusing on optimizing existing identifying new biomarkers, developing innovative therapeutic approaches.The potential medicine combination offers hope for improving survival rates quality life patients.

Language: Английский

Citations

0